Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. completed a private placement with RA Capital Management, selling 1,030,354 common shares at $6.785 each and pre-funded warrants for up to 3,391,164 shares at $6.7849, plus warrants for 4,421,518 shares at a $10.00 exercise price, for gross proceeds of about $30 million.

In March 2026 it also sold 2,994,441 common shares under its at-the-market sales agreement for net proceeds of about $19.8 million. After these transactions, it had 22,543,316 common shares outstanding and pre-funded warrants for 4,005,556 shares, and expects its liquidity to fund operations into late in the third quarter of 2026.

Insights

Biotech equity analyst

Karyopharm strengthens near-term liquidity with equity and warrant financing.

Karyopharm Therapeutics raised equity capital through a private placement with RA Capital and additional at-the-market share sales. The deal mixes common stock, pre-funded warrants, and traditional warrants, providing flexibility on when some shares may actually be issued.

The private placement generated about $30 million in gross proceeds, while the at-the-market program added about $19.8 million net. Following these issuances, the company reports 22,543,316 common shares outstanding and pre-funded warrants for 4,005,556 shares, indicating potential future dilution if all instruments are exercised.

The company states that existing liquidity, together with revenue sources, is expected to fund current operating plans into late in the third quarter of 2026. This clarifies the near-term cash runway but also signals that additional financing or business progress may be needed beyond that timeframe, depending on future developments.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false000150380200015038022026-03-272026-03-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 27, 2026

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36167				26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)				(IRS Employer Identification No.)
85 Wells Avenue, 2nd Floor Newton, Massachusetts				02459
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share to the Investor in a private placement (collectively, the “Private Placement”).

The Private Placement closed on March 26, 2026 and resulted in gross proceeds of approximately $30 million, before placement agent fees and offering expenses. In addition, in March 2026, the Company issued and sold an aggregate of 2,994,441 shares of Common Stock under its Open Market Sale AgreementSM, by and between the Company and Jefferies LLC, dated February 17, 2023 for total proceeds, net of sales commissions, of approximately $19.8 million, which amount includes the 1,100,844 shares disclosed by the Company in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 24, 2026.

Following the closing of these transactions, the Company will have 22,543,316 shares of Common Stock outstanding and pre-funded warrants to purchase an aggregate of 4,005,556 shares of Common Stock outstanding. The Company expects that its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into late in the third quarter of 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		KARYOPHARM THERAPEUTICS INC.
Date: March 27, 2026		By:	/s/ Michael Mano
			Michael Mano
			Executive Vice President, Chief Legal Officer and Secretary

FAQ

How much capital did Karyopharm Therapeutics (KPTI) raise in the March 2026 transactions?

Karyopharm raised about $30 million in gross proceeds from a private placement and an additional $19.8 million in net proceeds from at-the-market share sales. Together, these transactions significantly boosted the company’s cash resources for near-term operating needs.

What securities did Karyopharm Therapeutics (KPTI) issue to RA Capital Management?

Karyopharm agreed to sell RA Capital 1,030,354 common shares at $6.785 each, pre-funded warrants for up to 3,391,164 shares at $6.7849, and accompanying warrants for 4,421,518 shares at a $10.00 exercise price, all in a private placement.

How many shares did Karyopharm Therapeutics (KPTI) sell under its at-the-market program?

In March 2026, Karyopharm sold an aggregate of 2,994,441 common shares under its at-the-market sales agreement with Jefferies LLC. These sales generated approximately $19.8 million in net proceeds after sales commissions, supplementing cash from the private placement.

What is Karyopharm Therapeutics’ (KPTI) share count after the March 2026 financings?

After completing the private placement and at-the-market share sales, Karyopharm reported 22,543,316 common shares outstanding. It also had pre-funded warrants outstanding to purchase an additional 4,005,556 shares of common stock, which could be exercised in the future.

How long does Karyopharm Therapeutics (KPTI) expect its current liquidity to last?

The company expects its existing liquidity, together with cash flow from net product revenue and license and other revenue, will fund current operating plans into late in the third quarter of 2026. This guidance reflects the impact of the recent financings on its cash runway.

What type of financing structure did Karyopharm Therapeutics (KPTI) use in its March 2026 deal?

Karyopharm used a private placement structure with RA Capital, issuing common stock, pre-funded warrants, and traditional warrants. This structure raises immediate cash while spreading potential future share issuance over time through warrant exercises, subject to investor decisions.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.1 KB